Kanarb is the No.1 amongst ARBs available on the market in Korea.
Globally, we have business partnership for this product in 51 countries
worldwide, that implies that Kanarb is being recognized internationally.
There are several strong points and benefits of Kanarb that we
want to emphasize on as below;
- Brand name in Korea : Kanarb®
- INN name : Fimasartan
- New ARB (Angiotensin II Receptor Blocker) in-house developed
and manufactured by Boryung
- No.1 amongst ARBs available on the market in Korea
- Under business partnership in 51 countries worldwide, implying
that Kanarb is being recognized internationally
- Fimasartan-containing combination drugs available as well
Fimasartan+HCTZ,
Fimasartan+Amlodipine, Fimasartan+Rosuvastatin
1)
Strong
Fimsartan, owing to its chemical structure, has strong binding
affinity to AT1 receptor when compared with other ARBs
2)
Superior
Fimasartan showed superior effect in lowering BP and
significantly higher response rate when compared with Losartan and Valsartan
in our clinical studies
3)
Stable
Fimasartan maintained its anti-hypertensive effect throughout an
interval of 24 hours in our ABPM study
4)
Safe
Fimasartan showed low adverse event rate and low discontinuation
rate in our Phase IV study
KR
